Compare AESI & VCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AESI | VCEL |
|---|---|---|
| Founded | 2017 | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 1.7B |
| IPO Year | 2023 | 1996 |
| Metric | AESI | VCEL |
|---|---|---|
| Price | $13.96 | $47.18 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 6 | 5 |
| Target Price | $13.17 | ★ $57.75 |
| AVG Volume (30 Days) | ★ 2.7M | 716.6K |
| Earning Date | 05-04-2026 | 05-07-2026 |
| Dividend Yield | ★ 2.91% | N/A |
| EPS Growth | N/A | ★ 60.00 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,095,310,000.00 | $276,259,000.00 |
| Revenue This Year | $2.71 | $19.40 |
| Revenue Next Year | $17.78 | $18.24 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 3.73 | ★ 16.45 |
| 52 Week Low | $7.64 | $28.95 |
| 52 Week High | $20.13 | $47.79 |
| Indicator | AESI | VCEL |
|---|---|---|
| Relative Strength Index (RSI) | 34.62 | 77.13 |
| Support Level | $10.59 | $32.47 |
| Resistance Level | $14.23 | N/A |
| Average True Range (ATR) | 0.86 | 1.73 |
| MACD | -0.25 | 0.37 |
| Stochastic Oscillator | 13.45 | 98.32 |
Atlas Energy Solutions Inc is a provider of proppant and logistics services to the oil and natural gas industry within the Permian Basin of West Texas and New Mexico, the active oil and natural gas basin in North America. Proppant is necessary to facilitate the recovery of hydrocarbons from oil and natural gas wells. One hundred percent of its sand reserves are located in Winkler and Ward Counties, Texas, within the Permian Basin, and its operations consist of proppant production and processing facilities, including two facilities near Kermit, Texas, and a third facility near Monahans, Texas.
Vericel Corp is a fully integrated commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.